FGFR1 and non-small cell lung carcinoma: This covalent binding inhibits FGFR1 activity, thereby blocking the PI3K/AKT/mTOR and RAS/MAPK pathways and suppressing the survival and proliferation of FGFR1-amplified and mutated non-small-cell lung cancer cells [61].